A red-hot anti-aging strategy quietly passed its first test earlier this year after 14 volunteers took drugs meant to kill off old, toxic cells in their bodies.
The small study in people with lung disease, reported in January, is being billed as the first attempt at “senolytics,” or employing drugs to clear people’s bodies of aged, toxic cells. Some researchers think this strategy could eventually be employed in healthy people to delay aging.
“This gives us to some extent a green light to go on to larger trials,” says James Kirkland, a Mayo Clinic professor who helped lead the trial, carried out in clinics in Texas and at Wake Forest University starting in 2016.
Patients took two pills that Kirkland and his colleagues believed could selectively get rid of aged cells: the leukemia drug dasatinib and a supplement called quercetin.
It is early days for drugs meant to slow aging, and some breathed a sigh of relief that patients in this first-of-a-kind study didn’t suffer serious side-effects from the drugs. “My worry is we should not leap into this too fast, because if there’s a mistake or something we don’t understand, it could set the field back,” says Judith Campisi, a professor at the Buck Institute for Research on Aging in Novato, California.
This was a pilot trial—not even in the first phase of a three-part sequence of trials needed to win approval by the US Food and Drug Administration. So, officially, it showed nothing about aging at all.
All 14 patients suffered from a fatal, hard-to-treat lung condition called idiopathic pulmonary fibrosis, which explains why they were willing to participate in the experiment. The doctors found that nine doses of the two pills over three weeks did seem to improve patients’ ability to walk a bit farther in the same amount of time, and several other measures of well-being.
A bubble of commercial enthusiasm has been building around the idea that aging could be postponed, or its effects tempered, using drug treatments. A company called Unity Biotechnology of Brisbane, California, is developing two senolytic drugs, the first of which is in a phase 1 clinical trial for osteoarthritis—it’s being injected into people’s knees. Campisi is a cofounder of Unity, and Kirkland also holds shares in the public company, which is currently worth about half a billion dollars.
Image Credit: James Kirkland, Mayo Clinic professor. Mayo Clinic
News This Week
Inventors and scientists have been continuously working towards reducing the size of technological components. Room-sized computers to laptops that are slimmer than a pane of glass? It’s done. Huge bulky telephones to smartphones that [...]
You have witnessed a variety of nano-devices that were designed for tasks including delivering medicines within the body. All of them used to move in a variety of ways. However, the latest nano-device is [...]
Netra Rajesh is an undergraduate Engineering Science student specializing in Biomedical Systems Engineering. She is currently on her Professional Experience Year (PEY) at the Massachusetts Institute of Technology where her research lies at the [...]
Nearly half of the companies in Europe that call themselves AI start-ups don't in fact use artificial intelligence, a new report found. The research, published Tuesday by London-based venture capital firm MMC Ventures, found [...]
A new quantum sensor developed by researchers at the University of Waterloo's Institute for Quantum Computing (IQC) has proven it can outperform existing technologies and promises significant advancements in long-range 3D imaging and monitoring [...]
Summary: Researchers use nanotech to enhance vision in mice, enabling them to see infrared light as well as visible light. Source: Cell Press. Mice with vision enhanced by nanotechnology were able to see infrared [...]
Immune Aspects of Biopharmaceuticals and Nanomedicines Available from CRC Press 1st Edition Raj Bawa, Janos Szebeni, Thomas J Webster, Gerald F. Audette The enormous advances in the immunology of biotherapeutics and nanomedicines in the [...]
Artificial Intelligence - Ethics, Governance and Policy Challenges by Andrea Renda and CEPS Think Tank released. About the report: CEPS is launching a Task Force to try to bring back the AI debate to [...]
The Nanofacturing consortium has worked on a pan-European nanopharmaceutical project to develop new manufacturing methods and improve supply chain co-ordination to advance treatments for rare cancers, autoimmune diseases and viral infections. The Nanofacturing collaboration [...]
You know those little motes or floaters you that you sometimes see moving in your vision? Well, someday very soon, those could be robots. An international team of medical researchers has unveiled a new [...]
Scientists at the Helmholtz Zentrum München, a partner in the German Center for Lung Research, have presented a new imaging method in the scientific journal ACS Nano ("Three-Dimensional Quantitative Co-Mapping of Pulmonary Morphology and [...]
Note: This videoblog is in German. It was produced by the Institute of Art & Art Theory of the University of Cologne. Humanity faces epochal challenges in the age of digitization. In particular, [...]
Nanoscale drug-delivery capsules that release their therapeutic cargo when triggered by a temperature change could boost the efficacy and reduce the side effects of many drugs. Researchers at RIKEN have combined lipids and peptides [...]